LifeSciences BC > News > Member Announcements

Arbutus Announces Preliminary Phase 1a/1b Clinical Trial Results for AB-506, an Oral Capsid Inhibitor in Development for People with Chronic Hepatitis B

July 15, 2019
Arbutus Biopharma Corp.

Results demonstrate that AB-506 is a potent capsid inhibitor Phase 1a/1b clinical trial to continue with the enrollment of further cohorts Conference call and webcast scheduled today at 4:45 pm ET WARMINSTER, Pa., July 15, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced preliminary results from a Phase … Continue reading Arbutus Announces Preliminary Phase 1a/1b Clinical Trial Results for AB-506, an Oral Capsid Inhibitor in Development for People with Chronic Hepatitis B

DelMar Announces Relocation of Company Headquarters to San Diego

July 10, 2019
DelMar Pharmaceuticals Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., July 10, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of novel cancer therapies, announced today that it has initiated the process of relocating the Company’s headquarters from Vancouver, British Columbia to San Diego, CA. The move is intended … Continue reading DelMar Announces Relocation of Company Headquarters to San Diego

Arbutus Sells Part of its ONPATTRO™ (patisiran) Royalty Interest to OMERS

July 2, 2019
Arbutus Biopharma Corp.

Arbutus to receive $20 million in gross proceeds before advisory fees while retaining significant downstream economics  Runway extended with non-dilutive capital WARMINSTER, Pa., July 02, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the sale of part of its royalty interest on future global net sales of ONPATTRO™ (patisiran), an … Continue reading Arbutus Sells Part of its ONPATTRO™ (patisiran) Royalty Interest to OMERS

Delmar Pharmaceuticals Announces Termination Of Rights Offering

June 27, 2019
DelMar Pharmaceuticals Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., June 27, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced it has terminated the rights offering of its securities previously announced on April 18, 2019. The termination results from an assessment … Continue reading Delmar Pharmaceuticals Announces Termination Of Rights Offering

DelMar Pharmaceuticals Announces Extension Of Rights Offering To July 12, 2019

June 26, 2019
DelMar Pharmaceuticals Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., June 25, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it has completed the rights offering period and will be extending the subscription period until 5:00 PM Eastern time … Continue reading DelMar Pharmaceuticals Announces Extension Of Rights Offering To July 12, 2019

SCN Launches Funding Competition to Support Translational Stem Cell Research Across Canada

June 21, 2019
Stem Cell Network

June 13, 2019 (Ottawa) The Stem Cell Network is pleased to launch a new national research funding competition comprised of four translational research programs in stem cell and regenerative medicine. The first round opened today to support innovative research that will ultimately realize both health and economic benefits for Canadians. Over the next three years, SCN … Continue reading SCN Launches Funding Competition to Support Translational Stem Cell Research Across Canada

Arbutus receives regulatory clearance to initiate Phase 1a/1b Clinical Trial of AB-7

June 20, 2019

– AB-729 is a subcutaneously-administered RNAi agent targeting HBV replication and HBsAg antigen production – Supports corporate objective to combine AB-729 with AB-506, Arbutus’ proprietary oral capsid inhibitor WARMINSTER, Pa., June 20, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced it has received regulatory clearance to initiate … Continue reading Arbutus receives regulatory clearance to initiate Phase 1a/1b Clinical Trial of AB-7

Arbutus to Participate at JMP Securities Life Sciences Conference

June 13, 2019

WARMINSTER, Pa., June 13, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia and Dr. Gaston Picchio will participate in a fireside chat at JMP Securities Life Sciences Conference at 10:00 am ET on Thursday, June 20, 2019. A live webcast of the fireside chat can be accessed through the Investors section of … Continue reading Arbutus to Participate at JMP Securities Life Sciences Conference

Arbutus to Participate at JMP Securities Life Sciences Conference

June 13, 2019
Arbutus Biopharma

WARMINSTER, Pa., June 13, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia and Dr. Gaston Picchio will participate in a fireside chat at JMP Securities Life Sciences Conference at 10:00 am ET on Thursday, June 20, 2019. A live webcast of the fireside chat can be accessed through the Investors section of … Continue reading Arbutus to Participate at JMP Securities Life Sciences Conference

Delmar Pharmaceuticals Updates The Terms Of Previously Announced Rights Offering

June 11, 2019

June 11, 2019 VANCOUVER, British Columbia and MENLO PARK, Calif., /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it has adjusted certain pricing information and key dates for its previously announced rights offering.  The subscription period … Continue reading Delmar Pharmaceuticals Updates The Terms Of Previously Announced Rights Offering